Common errors made in the diagnosis and treatment of epilepsy

Seminars in Neurology

Volumn 28, Issue 3, 2008, Pages 364-378

  Kanner, Andres M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiepileptic drugs; Applied pharmacokinetics; Intractable epilepsy; Nonepileptic seizures; Status epilepticus

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DIAZEPAM; ESCITALOPRAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FELODIPINE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MIRTAZAPINE; NIMODIPINE; OXCARBAZEPINE; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SERTRALINE; SIMVASTATIN; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; WARFARIN;

ALBUMIN BLOOD LEVEL; ANAMNESIS; ANXIETY DISORDER; AREA UNDER THE CURVE; ATAXIA; ATTENTION DEFICIT DISORDER; BEDTIME DOSAGE; BLOOD CELL COUNT; BLURRED VISION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIAGNOSTIC ERROR; DIPLOPIA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EMERGENCY WARD; EPILEPSY; EPILEPTIC STATE; FATIGUE; FOCAL EPILEPSY; FRONTAL LOBE EPILEPSY; HEMOGLOBIN BLOOD LEVEL; HIP FRACTURE; HOSPITAL DISCHARGE; HUMAN; INTRACTABLE EPILEPSY; LABORATORY TEST; LOW DRUG DOSE; LUMBAR PUNCTURE; MACULOPAPULAR RASH; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; MYOCLONUS EPILEPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SEIZURE; SUICIDAL IDEATION; TEMPORAL LOBE EPILEPSY; THERAPY EFFECT; TONIC CLONIC SEIZURE; TREATMENT DURATION; TREATMENT FAILURE; VERTIGO; VOMITING;

ADULT; ANTICONVULSANTS; CLINICAL PROTOCOLS; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; DIAGNOSTIC IMAGING; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 49149124442     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1079341     Document Type: Review

References (50)

1. Kanner AM. Psychogenic pseudoseizures: semiology and pathogenic mechanisms. In: Luders HO, Noachtar S, eds. The Epileptic Seizures: Pathophysiology and Clinical Semiology. New York, NY: Churchill Livingstone; 2000:766-773
2. Kanner AM. Psychogenic seizures and the supplementary sensory motor area. In: HO Luders, ed. The Supplementary Sensory Motor Area. Advances in Neurology. Vol. 70. New York, NY: Raven Press; 1996:461-466
3. Kanner AM, Iriarte J. Psychogenic pseudoseizures: differential diagnosis. In: Kotagal P, Luders HO, eds. Etiologies of the Epilepsies. San Diego, CA: Academic Press; 1999:509-518
4. Jallon P, Latour P. Epidemiology of idiopathic generalized epilepsies. Epilepsia 2005;46(suppl 9):10-14
5. Welty TE. Juvenile myoclonic epilepsy: epidemiology, pathophysiology, and management. Paediatr Drugs 2006;8: 303-310
6. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319
7. DeLorenzo RJ. Epidemiology and clinical presentation of status epilepticus. Adv Neurol 2006;97:199-215
8. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998;339:792-798
9. DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998;39:833-840
10. Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002;43:993-1000
11. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ; Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68: 402-408
12. Mohanraj R, Brodie MJ. Pharmacological outcomes in newly diagnosed epilepsy. Epilepsy Behav 2005;6:382-387
13. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165-175
14. Arroyo S, Dodson WE, Privitera MD, et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 2005;112:214-222
15. Trimble MR, Mula M. Antiepileptic drug interactions in patients requiring psychiatric drug treatment. In: Majkowski J, Bourgeois B, Patsalos P, Mattson R, eds. Antiepileptic Drugs: Combination Therapy and Interactions. Cambridge: Cambridge University Press; 2005:350-368
16. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-481
17. Sitsen J, Maris F, Timmer C. Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur J Drug Metab Pharmacokinet 2001;26(1-2):109-121
18. Pihlsgard M, Eliasson E. Significant reduction of sertraline plasma levels by carbamazepine and phenytoin. Eur J Clin Pharmacol 2002;57:915-916
19. Majkowski J, Patsalos PN. Interaction between epileptic and non-epileptic drugs. In: Majkowski J, Bourgeois B, Patsalos P, Mattson R, eds. Antiepileptic Drugs: Combination Therapy and Interactions. Cambridge: Cambridge University Press; 2005:139-177
20. Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mjorndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 2004;59:879-882
21. Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000;356:285-290
22. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999;66:589-593
23. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64:1868-1873
24. Leppik IE. Epilepsy in the elderly. Epilepsia 2006;47(suppl 1): 65-70
25. Garrard J, Harms S, Hardie N, et al. Antiepileptic drug use in nursing home admissions. Ann Neurol 2003;54: 75-85
26. Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA. Long-term anticonvulsant therapy leads to low bone mineral density: evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000;108:37-43
27. Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999;99:269-275
28. Annegers JF, Melton LJ III, Sun CA, Hauser WA. Risk of age-related fractures in patients with unprovoked seizures. Epilepsia 1989;30:348-355
29. Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001;58:1369-1374
30. Pack AM, Morrell MJ. Treatment of women with epilepsy. Semin Neurol 2002;22:289-298
31. Engel J Jr, Wiebe S, French J. Practice parameter: temporal lobe and localized neocortical resections for epilepsy. Report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 2003;60:538-547
32. Mani J, Gupta A, Mascha E, et al. Postoperative seizures after extratemporal resections and hemispherectomy in pediatric epilepsy. Neurology 2006;66:1038-1043
33. Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998;51:1256-1262
34. Spooner CG, Berkovic SF, Mitchell LA, Wrennall JA, Harvey AS. New-onset temporal lobe epilepsy in children: lesion on MRI predicts poor seizure outcome. Neurology 2006;67:2147-2153
35. Dlugos DJ. The early identification of candidates for epilepsy surgery. Arch Neurol 2001;58:1543-1546
36. Gilliam F, Kuzniecky R, Faught E, et al. Patient-validated content of epilepsy-specific quality-of-life measurement. Epilepsia 1997;38:233-236
37. Lehrner J, Kalchmayr R, Series W, et al. Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients. Seizure 1999;8:88-92
38. Perrine K, Hermann BP, Meador KJ, et al. The relationship of neuropsychological functioning to quality of life in epilepsy [see comments]. Arch Neurol 1995;52:997-1003
39. Boylan LS, Flint LA, Labovitz DL, Jackson SC, Starner K, Devinsky O. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology 2004;62:258-261
40. Kanner AM, Wuu J, Barry J, Hermann B, Meador KJ, Gilliam F. Atypical depressive episodes in epilepsy: a study of their clinical characteristics and impact on quality of life. Neurology 2004;62(suppl 5):A249
41. Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry 1997;170:205-228
42. Jones JE, Hermann BP, Barry JJ, Gilliam FG, Kanner AM, Meador KJ. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav 2003;4(suppl 3):S31-S38
43. Kanner AM. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms and treatment. Biol Psychiatry 2003;54:388-398
44. Kanner AM. Current review in clinical science. Depression in epilepsy: a neurobiologic perspective. Epilepsy Curr 2005;5: 21-27
45. Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62:345-354
46. Dunn DW, Austin JK, Harezlak J, Ambrosius WT. ADHD and epilepsy in childhood. Dev Med Child Neurol 2003; 45:50-54
47. Hesdorffer DC, Ludvigsson P, Olafsson E, Gudmundsson G, Kjartansson O, Hauser WA. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry 2004;61:731-736
48. Feldman H, Crumine P, Handen BL, Alvin R, Teodori J. Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child 1989;143:1081-1086
49. Gross-Tsur V, Manor O, van der Meere J, Joseph A, Shalev RS. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective?. J Pediatr 1997;130:670-674
50. Ott D, Caplan R, Guthrie D, et al. Measures of psychopathology in children with complex partial seizures and primary generalized epilepsy with absence. J Am Acad Child Adolesc Psychiatry 2001;40:907-914